A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
Clinical trial NCT05846516 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05846516
- Sponsor
- Boehringer Ingelheim
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-11
- Primary completion
- 2027-03-08
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.